Halyard Health Inc (NYSE:HYH) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Tuesday.
According to Zacks, “Halyard Health, Inc. is a medical technology company. It is focused on advancing health and healthcare by preventing infection, eliminating pain and speeding recovery. The Company sells surgical and infection prevention products for the operating room. Halyard offers products such as sterilization wraps, face masks, surgical drapes and gowns, closed suction catheters, pain pumps and enteral feeding tubes. It offers a range of medical device solutions including post-operative pain management solutions, minimally invasive interventional (or chronic) pain therapies, closed airway suction systems, and enteral feeding tubes. Halyard Health, Inc. is headquartered in Alpharetta, Georgia. “
HYH has been the topic of several other reports. Deutsche Bank AG downgraded Halyard Health from a “buy” rating to a “hold” rating and set a $35.00 price target on the stock. in a report on Thursday, December 15th. Stephens downgraded Halyard Health from an “overweight” rating to an “equal weight” rating in a report on Tuesday, February 28th. JMP Securities downgraded Halyard Health from an “outperform” rating to a “market perform” rating and set a $38.00 price target on the stock. in a report on Friday, January 6th. Finally, Stifel Nicolaus increased their price target on Halyard Health from $38.00 to $45.00 and gave the stock a “buy” rating in a report on Tuesday, February 28th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $39.75.
Halyard Health (NYSE:HYH) opened at 38.20 on Tuesday. The stock has a market cap of $1.78 billion, a PE ratio of 44.94 and a beta of 1.87. The firm’s 50-day moving average price is $39.69 and its 200-day moving average price is $36.98. Halyard Health has a 52 week low of $26.05 and a 52 week high of $41.84.
Halyard Health (NYSE:HYH) last issued its quarterly earnings data on Monday, February 27th. The company reported $0.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.06. Halyard Health had a return on equity of 8.63% and a net margin of 2.80%. The business had revenue of $410 million for the quarter, compared to the consensus estimate of $401.72 million. During the same period in the prior year, the business posted $0.57 earnings per share. The company’s quarterly revenue was up 2.1% compared to the same quarter last year. Equities analysts predict that Halyard Health will post $1.84 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This report was originally reported by Mideast Time and is owned by of Mideast Time. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.mideasttime.com/halyard-health-inc-hyh-lowered-to-sell-at-zacks-investment-research/1589697.html.
Several large investors have recently modified their holdings of the company. LS Investment Advisors LLC raised its position in Halyard Health by 7.0% in the third quarter. LS Investment Advisors LLC now owns 3,468 shares of the company’s stock valued at $120,000 after buying an additional 227 shares during the period. Bayesian Capital Management LP acquired a new position in Halyard Health during the fourth quarter valued at approximately $214,000. Zacks Investment Management acquired a new position in Halyard Health during the third quarter valued at approximately $236,000. Jarislowsky Fraser Ltd acquired a new position in Halyard Health during the fourth quarter valued at approximately $243,000. Finally, Acrospire Investment Management LLC raised its position in Halyard Health by 20.3% in the third quarter. Acrospire Investment Management LLC now owns 7,037 shares of the company’s stock valued at $244,000 after buying an additional 1,187 shares during the period. Hedge funds and other institutional investors own 87.50% of the company’s stock.
About Halyard Health
Halyard Health, Inc seeks to advance health and healthcare by preventing infection, eliminating pain and speeding recovery. The Company operates through two segments: Surgical and Infection Prevention (S&IP) and Medical Devices. Its S&IP business provides healthcare supplies and solutions that target the prevention of healthcare associated infections.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Halyard Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.